Home » USA Broker Ratings » DexCom, Inc. – Consenus Indicates Potential 12.1% Upside

DexCom, Inc. – Consenus Indicates Potential 12.1% Upside

DexCom, Inc. with ticker code (DXCM) now have 15 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 180 and 125 calculating the average target price we see 160.67. Now with the previous closing price of 143.36 this now indicates there is a potential upside of 12.1%. The 50 day MA is 134.46 and the 200 moving average now moves to 131.94. The market capitalisation for the company is $13,396m. Company Website: http://www.dexcom.com

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient’s mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.